DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 1,4-5,8-24 and 26-31 are pending.
Claims 4-5,8-24 and 26-31 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected groups and species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 11/10/2025.
Claim 1 is currently under consideration to the extent that they read upon Applicant’s elected species.
It is noted as best as can be interpreted from Applicant’s response, Applicant elected the composition of claim 1, wherein said election therefore includes:
The specific components present: at least one of the saponins recited in claim 1,
The saponin is water soluble,
The specific amount of the saponin: at least 5%,
No additional components were identified as present.
No specific components were identified as excluded.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1 (all claims currently under consideration) is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gomes et al (CA 3071684).
Gomes teaches an extract characterized in that it comprises at least one steroidal glycoside from selected from the group including furcreastatin (see entire document, for instance, claim 6, and page 4, lines 20-23).
It is noted that the instant claims are directed to a composition, wherein how the composition is obtained, including the source material, do not appear to materially change the composition itself. As such, the prior art teaching of furcreastatin reads on the instant claim.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claim 1 (all claims currently under consideration) is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-27 of copending Application No. 18/011,335 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims teach the presence of 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside, 5(6)-disdehydroyuccaloiside, furcreastatin and yuccaloiside (see entire claims set, for instance, claim 6) in an amount of 10-25% (see entire claims set, for instance, claim 8).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claim 1 (all claims currently under consideration) is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-28 of copending Application No. 18/011,326 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims teach the presence of 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside (see entire claims set, for instance, claim 9) in an amount of at least 5% (see entire claims set, for instance, claim 1).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claim 1 (all claims currently under consideration) is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-27 of copending Application No. 18/011,335 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims teach the presence of 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside, 5(6)-disdehydroyuccaloiside, furcreastatin and yuccaloiside (see entire claims set, for instance, claim 6) in an amount of 10-25% (see entire claims set, for instance, claim 8).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claim 1 (all claims currently under consideration) is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-25 of copending Application No. 18/011,341 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims teach the presence of 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside, 5(6)-disdehydroyuccaloiside, furcreastatin and yuccaloiside (see entire claims set, for instance, claim 7) in an amount of 15-25% (see entire claims set, for instance, claim 10).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claim 1 (all claims currently under consideration) is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-26 of copending Application No. 18/571905 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims teach the presence of 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside, 5(6)-disdehydroyuccaloiside, furcreastatin and yuccaloiside (see entire claims set, for instance, claim 12).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claim 1 (all claims currently under consideration) is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-20 of copending Application No. 18/571,922 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims teach the presence of 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside, 5(6)-disdehydroyuccaloiside, furcreastatin and yuccaloiside (see entire claims set, for instance, claim 3) in an amount of 0.1-10% (see entire claims set, for instance, claim 2).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TREVOR M LOVE whose telephone number is (571)270-5259. The examiner can normally be reached M-F typically 6:30-3.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 5712726175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TREVOR LOVE/Primary Examiner, Art Unit 1611